Pharmaceuticals

Global Primary Myelofibrosis Market 2026 projected to reach $1.14 billion by 2030

March 24, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Primary Myelofibrosis Market At The End Of The 2026–2030 Forecast Period?

The primary myelofibrosis market size has seen significant expansion in recent years. It is anticipated to increase from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The factors contributing to this growth in previous periods include a scarcity of treatment choices, challenges with timely and accurate diagnosis, insufficient public understanding of the condition, a dependence on traditional medical interventions, and a relatively small number of patients.

The primary myelofibrosis market size is anticipated to undergo substantial growth in the upcoming years. It is projected to reach $1.14 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.2%. This expansion during the forecast period is attributable to the development of novel targeted therapies, increasing clinical trial activities, advancements in genetic and molecular diagnostics, growing investment in hematology research, and the rising adoption of personalized medicine. Significant trends expected during this period include heightened awareness and early diagnosis of primary myelofibrosis, an expansion in targeted therapies and personalized treatment approaches, increased utilization of advanced diagnostic tools, growth in clinical trials and research activities, and a focus on patient support programs and disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Primary Myelofibrosis Market?

The expanding occurrence of myelofibrosis is projected to drive the growth of the primary myelofibrosis market moving forward. Myelofibrosis is defined as an uncommon form of bone marrow cancer that interferes with the body’s normal blood cell production, resulting in significant scarring within the bone marrow, which in turn causes severe anemia, weakness, fatigue, and an enlarged spleen. This increase in myelofibrosis prevalence is largely attributed to the global aging population, given that the condition predominantly impacts individuals over 60, with extended life expectancies leading to more diagnoses. The growing incidence of myelofibrosis contributes to better management of primary myelofibrosis through stimulating research, improving early detection, expanding treatment choices, and fostering enhanced clinical guidelines and specialized care. As an illustration, a report released in November 2024 by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, indicated that myelofibrosis affects 3.2 per 100,000 people in the UK, with an incidence rate of 0.6 per 100,000. Consequently, the rising prevalence of myelofibrosis is propelling the expansion of the primary myelofibrosis market.

What Segment Types Make Up The Primary Myelofibrosis Market?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Market Trends Are Creating New Opportunities In The Primary Myelofibrosis Market?

Leading companies within the primary myelofibrosis market are concentrating on developing innovative products, such as Janus kinase 2 inhibiting tablets, to enhance symptom control and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications designed to block the activity of the JAK2 enzyme, which plays a role in the abnormal signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets contribute to reducing spleen size, alleviating symptoms of fatigue and bone pain, and impeding the disease’s advancement. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. This medication is approved by South Korea’s Ministry of Food and Drug Safety and is intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara operates as an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms like anemia, enlarged spleen, and fatigue. Its approval is supported by clinical trial data that demonstrated significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

Who Are The Key Players Driving Competition In The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Read the full primary myelofibrosis market report here:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Regions Are Projected To Dominate The Primary Myelofibrosis Market In The Coming Years?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Myelofibrosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795